中国房颤患者抗心律失常药物处方现状与合理性分析:CAFR研究
基于中国房颤注册研究18 014例患者,43.23%使用口服抗心律失常药物,胺碘酮和普罗帕酮最常见。不遵循指南的AAD处方总体发生率为6.54%,多见于非三级医院和高血栓栓塞风险的老年患者。
要点
- AAD组以合并症较少的阵发性房颤患者为主,胺碘酮多用于合并器质性心脏病的持续性房颤。
- 三级医院患者更倾向使用AAD(OR=3.72),高龄、心衰、卒中/TIA等高危患者更倾向不用AAD。
- 不遵循指南的AAD处方总体发生率6.54%,非三级医院及高血栓栓塞风险老年患者比例更高。
核心结论
- 采用AAD治疗的房颤患者多为合并症少的阵发性房颤,胺碘酮使用者多为合并器质性心脏病的持续性房颤。
- 不遵循房颤管理指南的AAD处方比例较低,多见于非三级医院以及血栓栓塞风险为高危的老年患者。
研究设计与样本
- 基于中国房颤注册研究(CAFR),纳入2011年8月至2016年8月18 014例房颤患者病历资料。
- 按基线或随访中是否应用AAD分为AAD组7 788例(43.23%)和非AAD组10 226例(56.77%)。
- 采用随机森林回归法分析AAD应用的相关影响因素,并依据房颤管理指南分析用药合理性。
主要发现
- AAD组较非AAD组≥75岁(13.74% vs 29.44%)、持续性房颤(28.95% vs 45.80%)、心衰(8.29% vs 21.95%)比例更低(P<0.001)。
- 三级医院患者更倾向使用AAD(OR=3.72,95%CI 3.17-4.37),高龄(OR=0.47,95%CI 0.39-0.55)、持续性房颤(OR=0.66,95%CI 0.60-0.72)更倾向不用。
- 胺碘酮和普罗帕酮分别占AAD组的53.02%和41.23%;持续性房颤(OR=4.57)、冠心病(OR=4.14)、心衰(OR=2.07)更倾向用胺碘酮。
- 左心室射血分数正常(OR=0.31,95%CI 0.15-0.65)和低血栓栓塞风险(OR=0.78,95%CI 0.63-0.97)更倾向用普罗帕酮(P<0.001)。
- 不遵循指南的AAD治疗总体发生率为6.54%(480/7 340),胺碘酮亚组5.13%、普罗帕酮亚组8.35%。
关键数值与推荐
- 不遵循指南的AAD治疗总体发生率为6.54%(480/7 340)。
- 不合理用药在≥75岁(20.4% vs 12.95%)、高血栓栓塞风险(77.1% vs 58.99%)及非三级医院(7.1% vs 3.33%)比例较高(P<0.001)。
临床怎么用
- 处方AAD时应依据房颤管理指南评估适应证,尤其关注高龄、高血栓栓塞风险及非三级医院患者。
- 对合并器质性心脏病的持续性房颤,胺碘酮使用较多;LVEF正常且低血栓栓塞风险者普罗帕酮使用较多。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the practice patterns and the related factors of oral antiarrhythmic drug (AAD) treatment in Chinese patients with atrial fibrillation (AF), and to evaluate the compliance of AAD application to atrial fibrillation management guidelines. Methods: From August 2011 to August 2016, medical records from 18 014 patients with AF were analyzed based on data from the Chinese Atrial Fibrillation Registry trial. Patients were divided into AAD group (7 788 cases, 43.23%) and non-AAD group (10 226 cases, 56.77%) according to whether AAD was used at baseline or at the time of first use during follow-up. Amiodarone (4 129 cases, 53.02%) and propafenone (3 211 cases, 41.23%) were the mostly prescribed AAD and subgroup analysis was performed accordingly. Medical records were analyzed by random forest regression to evaluate the use of AAD and related factors in patients with AF, and the rationality of AAD was analyzed according to the guidelines for the management of atrial fibrillation. Result: A total of 18 014 patients were included in this study, of which 60.48% (10 895/18 014) were male patients, 22.65% (4 081/18 014) were elderly patients(≥75 years old), there were 7 788 patients (43.23%) in AAD group, and 10 226 patients(56.77%) in non-AAD group. Compared with the non-AAD group, the elderly patients (≥75 years old, 13.74%(1 070/7 788) vs. 29.44%(3 011/10 226)), persistent AF (28.95% (2 250/7 788) 45.80% (4 683/10 226)), heart failure(8.29% (646/7 788) vs. 21.95% (2 245/10 226)), stroke and (or) TIA(12.15% (946/7 788) vs. 19.95% (2 040/10 226)), renal dysfunction(16.36%(1 274/7 788) vs. 29.37% (3 003/10 226)), and high thromboembolism risk(60.17% (4 748/7 788) vs. 76.40% (7 813/10 226)) were less prevalent in the AAD subgroup (P<0.001). Multivariate analysis showed that patients in tertiary hospitals (OR=3.72, 95%CI 3.17-4.37) were more likely to use AAD, elderly patients (≥75 years old, OR=0.47, 95%CI 0.39-0.55), persistent atrial fibrillation (OR=0.66, 95%CI 0.60-0.72), and patients with heart failure (OR=0.54, 95%CI 0.47-0.63), stroke and (or) TIA (OR=0.77, 95%CI 0.68-0.87), renal dysfunction (OR=0.75, 95%CI 0.59-0.95) and high thromboembolism risk(OR=0.7, 95%CI 0.58-0.84) were more likely not to use AAD(P<0.05). In the AAD group, amiodarone and propafenone were the most commonly used AAD, accounting for 53.02% (4 129/7 788) and 41.23% (3 211/7 788), respectively. Multivariate analysis showed that patients with persistent atrial fibrillation (OR=4.57, 95%CI 3.94-5.29) and coronary heart disease (OR=4.14, 95%CI 3.03-5.64), heart failure (OR=2.07, 95%CI 1.48-2.89), non-ischemic cardiomyopathy (OR=4.84, 95%CI 2.41-9.73) were more likely to use amiodarone, and those with normal left ventricular ejection fraction (OR=0.31, 95%CI 0.15-0.65) and low thromboembolism risk (OR=0.78, 95%CI 0.63-0.97) were more likely to use propafenone (P<0.001). The overall incidence of AAD treatment, which was not indicated by the guidelines was 6.5% (480/7 340); 5.1% (212/4 129) in the amiodarone group and 8.3% (268/3 211) in the propafenone group, respectively. Compared with the rational AAD use group, the proportion of irrational drug use was higher in the elderly (≥75 years old) (20.4% (98/480) vs. 12.9% (887/6 860)), patients of high thromboembolism risk (77.1% (379/480) vs. 59.0% (4 047/6 860)), and in non-tertiary hospitals (7.1% (34/480) vs. 3.3% (299/6 860)), but lower in men(50.8% (244/480) vs. 64.5% (4 427/6 860)), P<0.001. Conclusions: The patients with paroxysmal atrial fibrillation, who were treated with AAD, were mostly patients with fewer complications, and the patients who were treated with amiodarone were mostly patients with persistent atrial fibrillation, patients were more likely to complicate with organic heart disease. The incidence of AAD that do not comply with the guidelines was low, and it was more common in non-tertiary hospitals and the elder patients with high thromboembolism risk. 目的: 探讨心房颤动(房颤)患者口服抗心律失常药物(AAD)的治疗情况及其相关影响因素,并且依据房颤管理指南分析处方的合理性。 方法: 收集2011年8月至2016年8月中国房颤注册研究中18 014例房颤患者的病历资料,按基线或随访中是否应用AAD,分为AAD组7 788例(43.23%)和非AAD组10 226例(56.77%),并对在AAD组中占绝大多数的胺碘酮4 129例(53.02%)和普罗帕酮3 211例(41.23%)进行亚组分析,采用随机森林回归法探讨AAD应用的相关影响因素,并依据房颤管理指南分析用药合理性。 结果: 纳入的18 014例房颤患者中,男性10 895例(60.48%),≥75岁的老年患者4 081例(22.65%)。与非AAD组相比,AAD组≥75岁[13.74%(1 070/7 788)比29.44%(3 011/10 226)],持续性房颤[28.90%(2 250/7 788)比45.80%(4 683/10 226)],合并心力衰竭[8.29%(646/7 788)比21.95%(2 245/10 226)],卒中/TIA[12.15%(946/7 788)比19.95%(2 040/ 10 226)],肾功能异常[16.36%(1 274/7 788)比29.37%(3 003/10 226)],血栓栓塞风险为高危[60.17%(4 748/7 788)比76.40%(7 813/10 226)]的患者比例较低(P均<0.001)。多因素分析结果显示,三级医院(OR=3.72,95%CI:3.17~4.37)的患者更倾向于应用AAD,老年(OR=0.47,95%CI:0.39~0.55)、持续性房颤(OR=0.66,95%CI:0.60~0.72)、以及合并心力衰竭(OR=0.54,95%CI:0.47~0.63)、卒中和/或短暂性脑缺血发作(OR=0.77,95%CI:0.68~0.87)、肾功能异常(OR=0.75,95%CI:0.59~0.95)及血栓栓塞风险为高危(OR=0.70,95%CI:0.58~0.84)的患者更倾向于不应用AAD,P均<0.05。胺碘酮和普罗帕酮是最常用的AAD,分别占AAD组的53.02%(4 129/7 788)和41.23%(3 211/7 788)。多因素分析显示,持续性房颤(OR=4.57,95%CI:3.94~5.29)、合并冠心病(OR=4.14,95%CI:3.03~5.64)、心力衰竭(OR=2.07,95%CI:1.48~2.89)、非缺血性心肌病(OR=4.84,95%CI:2.41~9.73)的房颤患者更倾向于应用胺碘酮,左心室射血分数正常(OR=0.31,95%CI:0.15~0.65)、血栓栓塞风险为低危(OR=0.78,95%CI:0.63~0.97)的患者更倾向于应用普罗帕酮,P均<0.001。不遵循指南建议的AAD治疗的总体发生率为6.54%(480/7 340),胺碘酮亚组和普罗帕酮亚分别为5.13%(212/4 129)和8.35%(268/3 211),与合理用药组相比,不合理用药在≥75岁[20.4%(98/480)比12.95%(887/6 860)]、血栓栓塞风险为高危[77.1%(379/480)比58.99%(4 047/6 860)]以及非三级医院的比例较高[7.1%(34/480)比3.33%(299/6 860)],男性不合理用药的比例较低[50.8%(244/480)比64.53%(4 427/6 860)](P均<0.001)。 结论: 房颤患者中,采用AAD治疗的多为合并症少的阵发性房颤患者,其中应用胺碘酮治疗的多为合并器质性心脏病的持续性房颤患者。不遵循房颤管理指南的AAD处方比例较低,多见于非三级医院以及血栓栓塞风险为高危的老年患者。.
引用
- Sun LJ, Du X, Liu SW, et al. [Current status of the clinical practice and analysis on the ratioanl prescription of antiarrhythmic drugs in Chinese patients with atrial fibrillation: Results from the Chinese Atrial Fibrillation Registry (CAFR) trial]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020. PMID: 32957756. doi:10.3760/cma.j.cn112148-20200103-00004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。